Kazia announces presentation of new data at AACR Annual Meeting [Yahoo! Finance]
Kazia Therapeutics Limited - American Depositary Shares (KZIA)
US:NASDAQ Investor Relations:
kaziatherapeutics.com
Company Research
Source: Yahoo! Finance
announce the presentation of new data for both its pipeline molecules, paxalisib and EVT801, at the upcoming Annual Meeting of the American Association of Cancer Research (AACR) in San Diego, California , from 5-10 April 2024 There will be three presentations in total at AACR, including data from the phase 1 study of EVT801 in advanced solid cancers. The data being presented will outline initial clinical data from the phase 1 study and provides support and direction for the next stage of the study. In addition, data will be presented on the results of the combination therapy of paxalisib and gemcitabine for patients with relapsed/recurrent atypical teratoid/rhabdoid tumors AT/RT. Based on these findings, the Pacific Pediatric Neuro-Oncology Consortium (PNOC) is planning to include this therapy in its next AT/RT international clinical trial. Summary of Abstracts Session PO.CL01.15 - Early Detection Biomarkers 1 April 7, 2024 – 1:30pm-5:00pm Abstract 1059 / 7: Biomarkers ana
Show less
Read more
Impact Snapshot
Event Time:
KZIA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KZIA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KZIA alerts
High impacting Kazia Therapeutics Limited - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
KZIA
News
- Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases [Yahoo! Finance]Yahoo! Finance
- Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseasesPR Newswire
- Kazia announces presentation of new data at AACR Annual MeetingPR Newswire
- Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint [Yahoo! Finance]Yahoo! Finance
- Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary EndpointPR Newswire
KZIA
Sec Filings
- 4/19/24 - Form 424B3
- 4/19/24 - Form 6-K
- 3/27/24 - Form 424B3
- KZIA's page on the SEC website